Poison Pill
A poison pill, formally called a shareholder rights plan, is a corporate defense mechanism that allows a company's board to issue new shares at a steep discount to existing shareholders (other than the hostile acquirer) when any single investor acquires more than a defined threshold of shares, diluting the acquirer's ownership and making an unsolicited takeover prohibitively expensive.
The poison pill is the most widely deployed anti-takeover defense in U.S. corporate governance. A shareholder rights plan is typically adopted by the board without shareholder approval, though institutional investors and proxy advisory firms increasingly push for shareholder ratification. The plan operates by distributing rights to existing shareholders that become exercisable — and potentially devastating to an acquirer — if a single investor crosses a defined ownership threshold, commonly set between 10% and 20% of outstanding shares.
When the trigger is crossed, rights holders (everyone except the triggering acquirer) can exercise their rights to purchase additional shares at a substantial discount — often 50% — to the prevailing market price. The resulting share issuance dramatically dilutes the acquirer's ownership percentage and economic interest, making it economically irrational to proceed with an acquisition without board approval. The board retains the power to redeem the rights for a nominal fee, effectively disabling the pill to facilitate a negotiated transaction.
Delaware courts, whose decisions govern the majority of large U.S. public companies incorporated in that state, have consistently upheld the legality of shareholder rights plans under the business judgment rule, provided the board adopts the plan for legitimate defensive purposes rather than purely to entrench management. The seminal Delaware cases establishing this framework include decisions from the Delaware Court of Chancery and the Delaware Supreme Court that balanced board authority against shareholder rights.
The strategic purpose of the poison pill is to force potential acquirers to negotiate with the board rather than executing a hostile tender offer directly to shareholders. By making a hostile acquisition effectively impossible without board approval, the pill gives the board time to evaluate competing bids, seek alternative transactions, or present a credible standalone value creation plan. Critics argue that poison pills can be used by entrenched management to block value-creating acquisitions that shareholders would otherwise accept.
Activist investors frequently demand that boards with in-place poison pills either redeem them or agree to submit the plan for shareholder ratification at the next annual meeting. Companies that adopt poison pills without shareholder approval often face negative recommendations from proxy advisory firms on director elections at subsequent shareholder meetings.